$5.87
2.09% yesterday
Nasdaq, Dec 24, 08:36 pm CET
ISIN
US68621F1021
Symbol
ORGO

Organogenesis Holdings Stock price

$5.87
+0.48 8.91% 1M
+2.41 69.65% 6M
+2.67 83.44% YTD
+2.69 84.59% 1Y
+3.28 126.64% 3Y
-0.59 9.13% 5Y
-3.88 39.80% 10Y
-3.88 39.80% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.12 2.09%
ISIN
US68621F1021
Symbol
ORGO
Industry

Key metrics

Basic
Market capitalization
$745.0m
Enterprise Value
$684.5m
Net debt
positive
Cash
$63.8m
Shares outstanding
126.9m
Valuation (TTM | estimate)
P/E
negative | 82.2
P/S
1.6 | 1.4
EV/Sales
1.5 | 1.3
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
77.4%
Return on Equity
-0.2%
ROCE
0.2%
ROIC
0.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$465.2m | $521.3m
EBITDA
$19.0m | $59.5m
EBIT
$859.0k | $18.6m
Net Income
$-13.4m | $9.1m
Free Cash Flow
$-51.7m
Growth (TTM | estimate)
Revenue
2.2% | 8.1%
EBITDA
-29.0% | 54.3%
EBIT
-91.4% | -13.7%
Net Income
-81.4% | 1,063.8%
Free Cash Flow
-1,427.8%
Margin (TTM | estimate)
Gross
74.5%
EBITDA
4.1% | 11.4%
EBIT
0.2%
Net
-2.9% | 1.7%
Free Cash Flow
-11.1%
More
EPS
$-0.1
FCF per Share
$-0.4
Short interest
24.8%
Employees
869
Rev per Employee
$550.0k
Show more

Is Organogenesis Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Organogenesis Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Organogenesis Holdings forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Organogenesis Holdings forecast:

Buy
88%
Hold
13%

Financial data from Organogenesis Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
465 465
2% 2%
100%
- Direct Costs 119 119
6% 6%
26%
347 347
1% 1%
74%
- Selling and Administrative Expenses 300 300
6% 6%
64%
- Research and Development Expense 46 46
9% 9%
10%
19 19
29% 29%
4%
- Depreciation and Amortization 18 18
8% 8%
4%
EBIT (Operating Income) EBIT 0.86 0.86
91% 91%
0%
Net Profit -13 -13
81% 81%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Organogenesis Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organogenesis Holdings Stock News

Neutral
GlobeNewsWire
one day ago
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026
Neutral
GlobeNewsWire
10 days ago
Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announce...
Positive
Seeking Alpha
14 days ago
Organogenesis receives a Buy rating, driven by Q3/2025 beats, raised guidance, and favorable CMS payment reform for skin substitute products. AWC revenues grew 31% year-over-year; 2025 guidance calls for AWC net revenues of $500–$525M (4–9% growth) and Surgical & Sports Medicine up 6–23%. ReNu's BLA submission is delayed by about two months, with a critical FDA pre-BLA meeting scheduled for 12/...
More Organogenesis Holdings News

Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Head office United States
CEO Gary Gillheeney
Employees 869
Founded 1985
Website investors.organogenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today